Vantage Investment Partners LLC Sells 2,605 Shares of IDEXX Laboratories, Inc. $IDXX

Vantage Investment Partners LLC reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,102 shares of the company’s stock after selling 2,605 shares during the period. IDEXX Laboratories comprises approximately 2.4% of Vantage Investment Partners LLC’s portfolio, making the stock its 19th biggest holding. Vantage Investment Partners LLC’s holdings in IDEXX Laboratories were worth $36,602,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. EverSource Wealth Advisors LLC grew its position in IDEXX Laboratories by 2.5% during the third quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock valued at $397,000 after acquiring an additional 15 shares during the last quarter. CWA Asset Management Group LLC grew its position in IDEXX Laboratories by 3.5% during the fourth quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after acquiring an additional 17 shares during the last quarter. Stratos Wealth Partners LTD. grew its holdings in shares of IDEXX Laboratories by 1.7% in the third quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock worth $683,000 after purchasing an additional 18 shares during the last quarter. Cary Street Partners Investment Advisory LLC grew its holdings in shares of IDEXX Laboratories by 11.5% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock worth $111,000 after purchasing an additional 18 shares during the last quarter. Finally, Rockland Trust Co. grew its holdings in shares of IDEXX Laboratories by 4.4% in the fourth quarter. Rockland Trust Co. now owns 425 shares of the company’s stock worth $288,000 after purchasing an additional 18 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Nimrata Hunt sold 1,758 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total value of $1,115,574.06. Following the completion of the sale, the executive vice president owned 18,141 shares of the company’s stock, valued at $11,511,734.37. This trade represents a 8.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total value of $15,338,011.30. Following the completion of the sale, the chief executive officer directly owned 83,606 shares of the company’s stock, valued at $54,975,125.30. The trade was a 21.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 27,777 shares of company stock valued at $18,235,113 in the last ninety days. 0.79% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

IDXX has been the topic of several recent analyst reports. BTIG Research cut their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Piper Sandler cut their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Finally, UBS Group cut their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Stock Up 1.1%

Shares of IDEXX Laboratories stock opened at $559.37 on Friday. The company’s 50 day moving average price is $566.51 and its 200-day moving average price is $642.70. IDEXX Laboratories, Inc. has a 52-week low of $496.61 and a 52-week high of $769.98. The stock has a market capitalization of $44.12 billion, a price-to-earnings ratio of 41.19, a P/E/G ratio of 3.21 and a beta of 1.58. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter last year, the firm posted $2.91 earnings per share. The firm’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.